The growth of the stent graft balloon catheter market is primarily driven by the increasing prevalence of cardiovascular ...

CorMedix addresses catheter infections with its new solution, DefenCath. Read more about CRMD stock’s potential as the ...

Market is expected to generate a market value of USD 1,541.3 million in 2023 and a market value of USD 2,668.6 million by 2023-2033, at a CAGR of 6%. The increase in the number of people suffering ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Since rolling out its pulsed field ablation system for treating atrial fibrillation earlier this year, Boston Scientific has ...

FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there w ...

Piper Jaffray has recently reduced Catheter Precision Inc (VTAK) stock to Neutral rating, as announced on August 13, 2019, according to Finviz. Analyst ratings are significant because they provide ...

Cormedix Inc. ( (CRMD) ) has realeased its Q3 earnings. Here is a breakdown of the information Cormedix Inc. presented to its investors.

Boston Scientific boosted its projection for 2024 sales growth, and is now targeting growth of 16.5%, compared with a previous estimate range between 13.5% and 14.5% from 2023 levels of $14.24 billion ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an ...

Good afternoon and welcome to the NVE Corporation Conference Call for the Quarter Ended September 30, 2024. I’m Dan Baker NVE ...